Europe Sarcopenia Treatment Market Forecast to 2030 - Regional Analysis - by Treatment Type and Distribution Channel

List of Tables

The Europe sarcopenia treatment market was valued at US$ 993.46 million in 2022 and is expected to reach US$ 1,467.81 million by 2030; it is estimated to register a CAGR of 5.0% from 2022 to 2030.

Rise in Malnutrition and Vitamin Deficiency Among Adults Boosts Europe Sarcopenia Treatment Market

Malnutrition is one of the major risk factors for sarcopenia. According to the WHO, approximately 2.3 billion adults worldwide were undernourished as of 2021, representing nearly 30% of the global population. Among the reported risk factors, protein-energy deficiency is a frequent cause of sarcopenia. Further, vitamin D deficiency or insufficiency is positively associated with an increased risk of multiple illnesses, such as cancer, obesity, cardiovascular disease, and sarcopenia. According to the National Institutes of Health (NIH), nearly 50% of the world's population suffers from vitamin D insufficiency, and ~1 billion people are vitamin D deficient.

Europe Sarcopenia Treatment Market Overview

The sarcopenia treatment market in Europe is segmented into Germany, France, the UK, Italy, Spain, and the Rest of Europe. Europe occupies a significant position in the global sarcopenia treatment market and is estimated to register a notable CAGR during the forecast period.

Germany is an attractive market due to its innovative approach toward healthcare. According to the Federal Statistical Office, health expenditure in this country amounted to US$ 474 billion in 2021. The awareness of sarcopenia and sarcopenic obesity (SO) is gradually increasing in aging societies across Germany. Sarcopenia and SO are comparatively uncommon (<5%) among German men aged 70 and above. Therefore, an upsurge in the cases of orthopedic disorders, coupled with the rising demand for nutritional supplements, drives the growth of the sarcopenia treatment market in Germany.

Europe Sarcopenia Treatment Market Revenue and Forecast to 2030 (US$ Million)

Europe Sarcopenia Treatment Market Segmentation

The Europe sarcopenia treatment market is categorized into treatment type, distribution channel, and country.

Based on treatment type, the Europe sarcopenia treatment market is segmented into vitamin D and calcium supplement, protein supplement, vitamin B12 supplement, and others. The vitamin D and calcium supplement segment held the largest Europe sarcopenia treatment market share in 2022.

In terms of distribution channel, the Europe sarcopenia treatment market is segmented into pharmacies, retail channels, online channels, and others. The pharmacies segment held the largest Europe sarcopenia treatment market share in 2022.

By country, the Europe sarcopenia treatment market is segmented into Germany, France, Italy, the UK, Spain, and the Rest of Europe. Germany dominated the Europe sarcopenia treatment market share in 2022.

Abbott Laboratories, Amway Corp, Bayer AG, GSK Plc, Metagenics LLC, Nestle Health Science SA, Novartis AG, Pfizer Inc, and Sanofi SA are some of the leading companies operating in the Europe sarcopenia treatment market.

Product Code: BMIRE00030430

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. Europe Sarcopenia Treatment Market - Key Industry Dynamics

4.1 Europe Sarcopenia Treatment Market - Key Industry Dynamics
4.2 Market Drivers
- 4.2.1 Upsurge in Geriatric Population
- 4.2.2 Rise in Malnutrition and Vitamin Deficiency Among Adults
4.3 Key Market Restraints:
- 4.3.1 Unavailability of Direct Interventions
4.4 Key Market Opportunities:
- 4.4.1 Products in Clinical Trial Phases
4.5 Future Trends:
- 4.5.1 Rising Awareness About Sarcopenia
4.6 Impact of Drivers and Restraints:

5. Sarcopenia Treatment Market - Europe Market Analysis

5.1 Europe Sarcopenia Treatment Market Revenue (US$ Million), 2020 - 2030
5.2 Europe Sarcopenia Treatment Market Forecast and Analysis

6. Europe Sarcopenia Treatment Market Analysis - By Treatment Type

6.1 Vitamin D and Calcium Supplement
- 6.1.1 Overview
- 6.1.2 Vitamin D and Calcium Supplement: Europe Sarcopenia Treatment Market, Revenue and Forecast to 2030 (US$ Million)
6.2 Protein Supplement
- 6.2.1 Overview
- 6.2.2 Protein Supplement: Europe Sarcopenia Treatment Market, Revenue and Forecast to 2030 (US$ Million)
6.3 Vitamin B12 Supplement
- 6.3.1 Overview
- 6.3.2 Vitamin B12 Supplement: Europe Sarcopenia Treatment Market, Revenue and Forecast to 2030 (US$ Million)
6.4 Others
- 6.4.1 Overview
- 6.4.2 Others: Europe Sarcopenia Treatment Market, Revenue and Forecast to 2030 (US$ Million)

7. Europe Sarcopenia Treatment Market Analysis - By Distribution Channel

7.1 Pharmacies
- 7.1.1 Overview
- 7.1.2 Pharmacies : Europe Sarcopenia Treatment Market Revenue and Forecast to 2030 (US$ Million)
7.2 Retail Channels
- 7.2.1 Overview
- 7.2.2 Retail Channels : Europe Sarcopenia Treatment Market, Revenue and Forecast to 2030 (US$ Million)
7.3 Online Channels
- 7.3.1 Overview
- 7.3.2 Online Channels : Europe Sarcopenia Treatment Market, Revenue and Forecast to 2030 (US$ Million)
7.4 Others
- 7.4.1 Overview
- 7.4.2 Others : Europe Sarcopenia Treatment Market Revenue and Forecast to 2030 (US$ Million)

8. Europe Sarcopenia Treatment Market - Country Analysis

8.1 Europe
- 8.1.1 Europe Sarcopenia Treatment Market Revenue and Forecast and Analysis - By Country
  - 8.1.1.1 Europe Sarcopenia Treatment Market Revenue and Forecast and Analysis - By Country
  - 8.1.1.2 Germany Sarcopenia Treatment Market Revenue and Forecast to 2030 (US$ Mn)
    - 8.1.1.2.1 Germany Sarcopenia Treatment Market Breakdown by Treatment Type
    - 8.1.1.2.2 Germany Sarcopenia Treatment Market Breakdown by Distribution Channel
  - 8.1.1.3 France Sarcopenia Treatment Market Revenue and Forecast to 2030 (US$ Mn)
    - 8.1.1.3.1 France Sarcopenia Treatment Market Breakdown by Treatment Type
    - 8.1.1.3.2 France Sarcopenia Treatment Market Breakdown by Distribution Channel
  - 8.1.1.4 United Kingdom Sarcopenia Treatment Market Revenue and Forecast to 2030 (US$ Mn)
    - 8.1.1.4.1 United Kingdom Sarcopenia Treatment Market Breakdown by Treatment Type
    - 8.1.1.4.2 United Kingdom Sarcopenia Treatment Market Breakdown by Distribution Channel
  - 8.1.1.5 Italy Sarcopenia Treatment Market Revenue and Forecast to 2030 (US$ Mn)
    - 8.1.1.5.1 Italy Sarcopenia Treatment Market Breakdown by Treatment Type
    - 8.1.1.5.2 Italy Sarcopenia Treatment Market Breakdown by Distribution Channel
  - 8.1.1.6 Spain Sarcopenia Treatment Market Revenue and Forecast to 2030 (US$ Mn)
    - 8.1.1.6.1 Spain Sarcopenia Treatment Market Breakdown by Treatment Type
    - 8.1.1.6.2 Spain Sarcopenia Treatment Market Breakdown by Distribution Channel
  - 8.1.1.7 Rest of Europe Sarcopenia Treatment Market Revenue and Forecast to 2030 (US$ Mn)
    - 8.1.1.7.1 Rest of Europe Sarcopenia Treatment Market Breakdown by Treatment Type
    - 8.1.1.7.2 Rest of Europe Sarcopenia Treatment Market Breakdown by Distribution Channel

9. Sarcopenia Treatment Market-Industry Landscape

9.1 Overview
9.2 Growth Strategies in the Sarcopenia Treatment Market
9.3 Inorganic Growth Strategies
- 9.3.1 Overview
9.4 Organic Growth Strategies
- 9.4.1 Overview

10. Company Profiles

10.1 Abbott Laboratories
- 10.1.1 Key Facts
- 10.1.2 Business Description
- 10.1.3 Products and Services
- 10.1.4 Financial Overview
- 10.1.5 SWOT Analysis
- 10.1.6 Key Developments
10.2 Bayer AG
- 10.2.1 Key Facts
- 10.2.2 Business Description
- 10.2.3 Products and Services
- 10.2.4 Financial Overview
- 10.2.5 SWOT Analysis
- 10.2.6 Key Developments
10.3 Metagenics LLC
- 10.3.1 Key Facts
- 10.3.2 Business Description
- 10.3.3 Products and Services
- 10.3.4 Financial Overview
- 10.3.5 SWOT Analysis
- 10.3.6 Key Developments
10.4 Nestle Health Science SA
- 10.4.1 Key Facts
- 10.4.2 Business Description
- 10.4.3 Products and Services
- 10.4.4 Financial Overview
- 10.4.5 SWOT Analysis
- 10.4.6 Key Developments
10.5 Novartis AG
- 10.5.1 Key Facts
- 10.5.2 Business Description
- 10.5.3 Products and Services
- 10.5.4 Financial Overview
- 10.5.5 SWOT Analysis
- 10.5.6 Key Developments
10.6 Pfizer Inc
- 10.6.1 Key Facts
- 10.6.2 Business Description
- 10.6.3 Products and Services
- 10.6.4 Financial Overview
- 10.6.5 SWOT Analysis
- 10.6.6 Key Developments
10.7 Sanofi SA
- 10.7.1 Key Facts
- 10.7.2 Business Description
- 10.7.3 Products and Services
- 10.7.4 Financial Overview
- 10.7.5 SWOT Analysis
- 10.7.6 Key Developments
10.8 Amway Corp
- 10.8.1 Key Facts
- 10.8.2 Business Description
- 10.8.3 Products and Services
- 10.8.4 Financial Overview
- 10.8.5 SWOT Analysis
- 10.8.6 Key Developments
10.9 GSK Plc
- 10.9.1 Key Facts
- 10.9.2 Business Description
- 10.9.3 Products and Services
- 10.9.4 Financial Overview
- 10.9.5 SWOT Analysis
- 10.9.6 Key Developments

11. Appendix

11.1 About The Insight Partners
11.2 Glossary of Terms